HOME >> MEDICINE >> NEWS
Contrast agent puts new light on diagnosing breast cancer

ast tissue, making it harder to distinguish between healthy tissue and questionable masses in mammograms, Frangioni says.

The new agent works by binding to micro-calcifications produced in breast cancers. Though scientists cant explain exactly why these calcifications occur, studies show that the calcifications in malignant breast tumors contain a higher proportion of a particular calcium salt called hydroxyapatite. In benign tumors, the predominant calcium salt is calcium oxalate.

By homing in on hydroxyapatite, we can target these malignant cells with a high degree of specificity, and that has the potential to improve the patients outcome, Frangioni says.

The contrast agents are designed using a combination of bisphosphonate, a type of drug used to strengthen bone, with a near-infrared fluorophore. When used with optical tomography, an imaging method that transmits near-infrared light through the body, doctors can reconstruct a three-dimensional image of tissues deep inside the breast, highlighting areas where malignant tumors appear.

The agent also may be used during surgery to pinpoint the location of hydroxyapatite, and therefore the breast cancer cells themselves, Frangioni notes.

His group began working to develop agents to target hydroxyapatite six years ago, but efforts were stalled by the inability to manufacture large quantities of the agent.

It was a chemical catch22, he says. Bisphosphonates are insoluble in anything but water, but to prepare large quantities of the substance for our studies, we need to perform the reaction in the absence of water.

Last year, Frangionis chemistry group, led by Bhushan, went back to the drawing board and devised a scheme that allowed them to synthesize the agents sans water. Once the compound was completely assembled, the researchers found a way to then make it water soluble.

Recent studies by the lab proved that the new agent works well in
'"/>


26-Mar-2007


Page: 1 2 3

Related medicine news :

1. Shark cartilage shows no benefit as a therapeutic agent for lung cancer
2. Targeted, oral agent Enzastaurin shows favorable results
3. Studies suggest investigational agent reduces disease activity in MS
4. Novel anti-oxidant and anti-inflammatory agent shows effectiveness on key endpoints in trial
5. MRI contrast agent can detect heart attack in the making
6. New reagent delivers a chemical breakthrough at FSU
7. High-resolution imaging with contrast agent shows promise in osteoarthritis research
8. Study suggests anesthetic agent may have rapid antidepressant effects
9. Alzheimers medication shows promise in treating nerve agent and pesticide poisoning
10. Cranberries contain possible anti-caries/anti-plaque agents
11. New contrast agents may be on horizon for better medical imaging

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... The American ... Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium ... 8. , In honor of Morris F. Collen, a pioneer in the field of ...
(Date:10/12/2017)... ... 2017 , ... Dr. Parsa Mohebi, the Los Angeles based ... the newly revamped Cosmetic Town journal section, featuring articles written by ... as Follicular Unit Extraction (FUE). , Dr. Mohebi says “I enjoy ...
(Date:10/12/2017)... ... ... On Saturday, October 21, the Health & Wellness Center at Florida Hospital ... for the American Heart Association Heart Walk. Teams of up to 10 people can ... their treadmills moving for 5 hours. Treadmills will start at 7:00 p.m. on Saturday, ...
(Date:10/12/2017)... ... October 12, 2017 , ... In the ... a year. In some states—like New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, ... retirement havens have extremely low property-tax rates, which contributes to the relatively lower ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... enhanced Pepper Flow promotional review platform at the Promotional Review Committee Compliance ... capabilities help marketers streamline the medical, legal, and regulatory review (MLR) process ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... Israel and NEW YORK , Sept. 27, ... with mobile health and big data solutions, today announced that its MyDario ... Please check your local TV listings for when The Dr. Oz Show ... ... season this month. ...
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
(Date:9/19/2017)... Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses ... today:   ... Jim ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and business ...
Breaking Medicine Technology:
Cached News: